Caris Life Sciences, Inc.

What they do

Caris provides whole exome and whole transcriptome sequencing (WES/WTS) tissue- and blood-based tumor profiling (MI Profile, Caris Assure) and whole genome sequencing (WGS)-based tests (Precision Whole Genome Platform, Caris Detect, Caris ChromoSeq). It also sells data and bioinformatics services to biopharma partners and has launched an AI prognostic tool (Caris MI Clarity) using computational pathology. Revenue comes primarily from clinical oncology case volume and biopharma collaborations.

Revenue drivers

• Molecular Profiling Services — Generated $252.3 million in Q2 2026, up 55% year over year, driven by higher clinical case volume and higher average selling price (ASP); comprises the bulk of total revenue.
• MI Profile Platform (tissue-based WES/WTS) — Approximately 48,300 MI Profile cases in Q2 2026, the main legacy product line and primary revenue contributor.
• Caris Assure Platform (blood-based WES/WTS) — Approximately 10,700 Caris Assure cases in Q2 2026; contributes to molecular profiling services volume growth (18% year-over-year total case increase).
• Biopharma partnerships — Provides data and bioinformatics services to partners (Moderna, AbbVie, Xencor, Merck KGaA, Genentech); contributes to revenue and uses the unique clinico-genomic dataset.

Recent performance

Q2 2026 revenue rose 45% year over year to $263.7 million; gross margin improved to 68% (from 63%); net loss narrowed to $0.6 million from $71.8 million. Operating cash flow was positive at $28.5 million and free cash flow was $6.4 million. Full-year 2025 revenue was $812.0 million with a net loss of $68.1 million; 2026 first-half revenue was $479.9 million. The company reported over 1,130,000 total profiles and 845,000 matched profiles through June 30, 2026.

Strategy

Caris is expanding its product portfolio beyond tissue-based profiling into blood-based tests (Caris Assure, Caris Detect) and whole genome sequencing (Caris ChromoSeq). It is investing in AI/ML-driven diagnostics (Caris MI Clarity) and using its large multi-modal dataset to power new solutions and biopharma collaborations. The company aims to address the full cancer care continuum from early detection to treatment monitoring, and it started a $100 million share repurchase program. Management emphasizes scaling the commercial engine to convert data depth into clinical products.

Risks

• Competitive and rapid change in precision medicine — The industry is highly competitive and subject to rapid technological change, which could erode Caris's market position.
• Dependence on tissue-based profiling — The majority of revenue still comes from tissue-based MI Profile; adoption of newer products (Assure, Detect) is not guaranteed.
• Commercial acceptance of new solutions — Launch success of Caris Detect, ChromoSeq, and MI Clarity is uncertain; validation studies and clinical trial results may not support commercial use.
• History of losses and profitability risk — Caris has incurred significant losses since inception and may not sustain profitability in the future despite recent positive cash flow.

Outlook

Management raised 2026 revenue guidance to $1.03–$1.04 billion, representing 27%–28% growth over 2025. They expect continued growth from molecular profiling services, new product launches, and biopharma collaborations. They also highlight operational momentum with record case volumes and improving gross margins.